Remove 2001 Remove Marketing Remove Nurses
article thumbnail

ReWalk Robotics announces the Appointment of Randel E. Richner, BSN, MPH to its Board of Directors

The Pharma Data

Richner received a Master of Public Health in Health Policy and Administration and a Bachelor of Science in Nursing from the University of Michigan in Ann Arbor, Michigan. develops, manufactures and markets wearable robotic exoskeletons for individuals with lower limb disabilities as a result of spinal cord injury or stroke.

article thumbnail

Article FDA Thank You In a new final rule, FDA carves out a regulatory niche for medical gases

Agency IQ

In 2001, the FDA issued a guidance to “alert hospitals, nursing homes, and other health care facilities to the hazards of medical gas mix-ups.”

FDA
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

PMA Preemption Decision Slides to the Bottom of the “Parallel Claim” Slippery Slope

Drug & Device Law

312 (2008), that essentially all product liability claims against manufacturers of FDA pre-market approved (“PMA”) medical devices were preempted. That’s a toxic mix, indeed, when combined with the plaintiffs’ bar’s latest concerted attempt to drive a form of birth control off the market through product liability litigation.

article thumbnail

A Painful Preemption Decision

Drug & Device Law

341, 352 (2001) (“neither an express pre-emption provision nor a saving clause bars the ordinary working of conflict pre-emption principles”). This regulation specifies the precise language for “liver”-related warnings on acetaminophen-containing products marketed for adult use. Buckman Co. Plaintiffs Legal Committee , 531 U.S.

article thumbnail

FDA and Off-Label Communication – Getting Closer to Truth

Drug & Device Law

341 (2001)), calls “off-label use,” so we go with the majority naming convention. T]hese marketing techniques influence use of the products based on elements other than the scientific content of the communication (as used herein, “persuasive marketing techniques”). Plaintiffs Legal Committee , 531 U.S.

FDA